CliffBio
small molecule

JORNAY PM

METHYLPHENIDATE HYDROCHLORIDE

Loss of exclusivityMarch 2032latest FDA-listed patent expiry
CompanyIRONSHORE PHARMACEUTICALS INC A WHOLLY OWNED SUB OF COLLEGIUM PHARMACEUTICAL INC

Drug detail

Brand nameJORNAY PM
Active ingredientMETHYLPHENIDATE HYDROCHLORIDE
Strength20MG
Dosage formCAPSULE, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2018
Marketing statusRX

Listed patents

PatentExpiresType
10292937March 2032use U-2357
9603809March 2032use U-2357
8916588March 2032use U-2357
9028868March 2032use U-2357
10617651March 2032use U-2357
9034902March 2032use U-2357
10881618March 2032use U-2357
11911518March 2032use U-2357
11241391March 2032use U-2357
11241392March 2032product
9498447March 2032product
9283214March 2032product
9023389March 2032product
10905652March 2032product
8927010March 2032product
10182995March 2032product

More from IRONSHORE PHARMACEUTICALS INC A WHOLLY OWNED SUB OF COLLEGIUM PHARMACEUTICAL INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

JORNAY PM patent cliff — loss of exclusivity March 2032 | CliffBio